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ABSTRACT
Introduction: We examined patient outcomes after Gamma Knife stereotactic radiosurgery (GKSRS)
salvage therapy for recurrent high-grade gliomas (HGGs) to determine whether tumor grade or
lesion size affected overall survival (OS) and progression-free survival (PFS).
Methods: This single-center retrospective study assessed radiographic response and clinical
outcomes following GKSRS salvage treatment of recurrent malignant gliomas (January 2005–
March 2014).
Results: A total of 121 patients (67 female) with 132 tumors were treated. Median (range) PFS was
4.7 (3.9-5.4) months for the cohort, 6.8 (4.6-8.9) months for initial grade 2 tumors, 4.2 (1.9-6.5)
months for initial grade 3 tumors, and 4.3 (3.7-4.9) months for initial grade 4 tumors. Patients with
small lesions (≤6.7 cm3; n = 53) had significantly longer median (range) PFS (6.8 [4.8-8.8], P=0.02).
Conclusions: GKSRS offers meaningful salvage therapy with minimal morbidity in appropriately
selected patients with focally recurrent HGGs.
Keywords: Gamma Knife; recurrent high-grade glioma; salvage therapy; stereotactic radiosurgery
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INTRODUCTION
Glioblastoma (GBM) accounts for approximately 15%
of all brain tumors.(1) Because GBMs are highly infiltrative and relatively resistant to radiation and chemotherapy,
most patients with GBM experience a recurrence within 1
year. It is considered rare for patients to survive more than
5 years after diagnosis, although reports of long-term survivors have been published.(2) The most recent advance is
the addition of tumor-treating fields (TTF), with a reported
20.9-month median overall survival for a cohort of 466
patients treated with upfront TTF in addition to standard
resection or biopsy plus radiation and temozolomide.(3)
However, even in the best-reported results to date in this
large study of 695 patients, the median progression-free
survival (PFS) was still only 6.7 months.(3)
Stereotactic radiosurgery delivered by the Gamma
Knife (Elekta, AB, Stockholm, Sweden) (GKSRS) or
other specialized treatment units offers the ability to
treat relatively deep, small areas of focally recurrent
high-grade glioma (HGG) in a single-day outpatient
setting through a non-surgically invasive approach with
a low risk of causing further deficits in the short term.
However, this technique has been criticized for its inability to treat the infiltrative nature of HGG and for the
risk of post-radiation treatment effect (PRTE).
This study sought to add to the current body of
knowledge regarding the outcomes of patients treated
with GKSRS as salvage therapy for recurrent HGG
to help physicians best determine when GKSRS is
an appropriate treatment option. We hypothesized
that overall survival (OS) and PFS would decrease as
tumor grade increased and that both OS and PFS would
decrease as lesion size increased.

MATERIAL AND METHODS
A single-center retrospective study was conducted
evaluating radiographic response and clinical outcomes
after GKSRS was administered to patients with recurrent gliomas. The institutional review board approved the
study and waived informed consent requirements. Data
were collected from hospital and medical office records,
and all available treatment and surveillance magnetic resonance images were reviewed as described below.
Inclusion Criteria
All adult patients treated with GKSRS for recurrent gliomas between January 1, 2005, and March 31, 2014, were
evaluated for inclusion. Patients with initial World Health
Organization (WHO) grade 1 tumors were excluded.
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Patients with WHO grade 2, 3, and 4 gliomas were included
based on initial pathologic tissue diagnosis regardless
of the time between diagnosis and salvage GKSRS. No
patients had GKSRS as a primary treatment. A biopsy was
not required before salvage treatment. However, during a
weekly review board meeting before patient treatment, a
consensus opinion was reached by a neurosurgeon, radiation oncologist, and neuroradiologist that a patient’s radiographic change was consistent with focal tumor progression
or malignant degeneration of prior lower-grade tumors and
was not consistent with PRTE. No patients with diffusely
infiltrative or nonenhancing tumors were treated in this
series. Previous grade 2 tumors were included because the
recurrences were felt to be of high grade due to the presence
of enhancing nodules in previously nonenhancing tumors.
Study Population and Treatment Technique
The decision to treat patients was made on an
individual basis and is reported in a retrospective
fashion. Per our institutional protocol, all cases
suspected to be recurrent HGG were presented and
reviewed in a multidisciplinary radiosurgical conference/tumor board before treatment to gain consensus approval for the appropriateness and safety of
GKSRS as a salvage therapy. It is important to note
that multiple options for therapy, including enrollment in clinical trials, were typically discussed and
were chosen many times by patients not included
in this study. Additionally, several patients in this
study had not responded to therapy after enrollment
in various clinical trials, and GKSRS was chosen as
their salvage treatment.
All patients were treated with the Leksell Gamma Knife
model C (Elekta, Stockholm, Sweden) prior to 2007 and
with the Perfexion model (Elekta) thereafter. T-1 weighted
SPGR gadolinium-enhanced MR images with 1-mm contiguous slices were obtained. The volume of the enhancing
nodule was outlined for treatment using the GammaPlan
(Elekta) software. The percentage of the target volume
coverage was calculated in all cases with 100% coverage
by the 50% isodose line achieved in nearly all cases. Typically, a generous coverage of the target beyond the enhancing margin was performed when the location was deemed
appropriate; however, an intentional, specific additional
margin beyond the edge of enhancement, as reported in
some other series, was not specifically prescribed.(4) The
mean and standard deviation for coverage beyond the margin, calculated by subtracting the target volume (mL) from
the treatment isodose line volume (mL), was 4.33 ± 6.63
mL. The dose at the 50% isodose line was 12-15 Gy, lower
than in other reported series and lower than typically prescribed for metastatic disease, with the goal of avoiding
PRTE as all patients had received prior high-dose inten-
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sity-modulated radiation therapy (IMRT) near the area of
salvage GKSRS.
Overall Survival and Progression-Free Survival
Analyses
To retrospectively differentiate tumor progression from
PRTE, we applied the Response Assessment in Neurooncology (RANO) criteria based on radiographic presentation. Disease progression was defined as greater than a 25%
increase in T1-enhanced lesion volume. Progression was
then subclassified as either in-field (within 50% isodose
margin), marginal (within 2 cm of 50% isodose margin),
or distant (greater than 2 cm away from 50% isodose line).
For classification as progressive disease, in-field and marginal disease progression criteria must have been met for
a minimum of 4 successive imaging dates. If progression
was maintained, the first date on which progression was
observed was established as the start date of progressive
disease. If 4 successive scans did not meet this requirement,
no date for progressive disease was assigned. However, if
distant disease progression was established at any point in
follow-up, the first date at which progression occurred was
determined to be the date of progressive disease. When
perfusion MRIs were available, focally increased relative cerebral blood volume corresponding to the region of
enhancement was confirmatory for progressive disease,
and low relative cerebral blood volume was deemed consistent with PRTE. If no imaging follow-up was available,
the halfway point between last follow-up and date of death
was used to estimate the date of disease progression.
Survival analyses were conducted for OS using the
date of death minus the date of initial resection. OS was
also computed using the date of death minus date of first
GKSRS. PFS was computed using the date of progression minus date of first GKSRS. Kaplan-Meier curves are
shown by initial tumor grade and by lesion size. Lesion
size was addressed as both a continuous and dichotomized variable using median value to large tumors (above
median) and small tumors (at or below median). For
patients with multiple lesions, the largest lesion size was
used to determine the patient’s tumor-size category.
Karnofsky Performance Status
The Karnofsky Performance Status (KPS) score, a
physician-assigned value, was used to evaluate patient
KPS. The KPS scale provides a score of 0–100 in
10-point intervals, each based on specific criteria, such
as the ability to work, care for oneself, and degree of
symptoms. A score of zero reflects a deceased patient,
and a score of 100 reflects no evidence of disease and
normal functional capacity.

Statistical Analysis
Our cohort is described using counts with percentages and means with standard deviations. Kaplan-Meier
analyses were used to estimate OS from initial resection
and OS and PFS from the time of GKSRS for the entire
cohort, by WHO tumor grade, and by lesion volume split
at the median to represent large (>6.7 cm3) versus small
(≤6.7 cm3) tumors. The number of events (deaths), censored cases, and patients exposed to risk at each interval
are reported. Mean and median survival estimates are
reported with standard errors and 95% confidence intervals. Although standard median survival statistics are
reported, we also provide mean survival as an additional
statistic to describe patient trajectory. Pairwise log-rank
tests were used to assess for statistically significant differences between survival estimates. KPS value differences were compared using a repeated-measures general
linear model with follow-up visit as the within-subjects
factor and KPS score as the dependent variable. P values
<0.05 were considered statistically significant. SPSS version 22 was used for analyses.

RESULTS
Our cohort consisted of 121 patients with 132
tumors who underwent GKSRS for recurrent gliomas. The mean patient age was 49.2±15.7 years,
and 67 of 121 (55.4%) were female. Initial tumor
grade was missing for 2 patients (Table 1). For the
remaining 119 patients, the initial tumor grade for
the majority was grade 4 (n=73, 61.3%), followed by
grade 3 (n= 27, 22.7%) and grade 2 (n=19, 16.0%).
Prior to GKSRS, 100% (n=121) of patients underwent resection, 71.1% (n=86) underwent re-resection, 91.7% (n=111) underwent IMRT, 14.0% (n=17)
were treated with carmustine implants, 21.5% (n=26)
were participants in a clinical trial, and 28.9% (n=35)
were administered BVZ.
Survival and Tumor Grade
Overall Survival after Initial Resection
Survival estimates for the combined cohort and
separated by tumor grade are reported in Table 2.
The median OS of the combined cohort was 26.0
(95% CI, 18.1-33.9) months and 86.0 (range 39.6132.4) months for patients with prior grade 2 tumors,
33.0 (range 26.2-40.3) months for grade 3, and 20.5
(range 17.5-23.5) months for grade 4. Patients with
small lesions (≤6.7 cm3) had significantly longer OS
with a median OS of 32.3 (range 25.2–39.5) months

Journal of Radiosurgery and SBRT

Vol. 6

2019     201

Cody J. Smith et al.

Table 1. Characteristics of cohort of 121 patients with
132 glioblastomas

Variable

No. (%)*

Age, mean±SD, yr

49.2±15.7

Sex

Progression-Free Survival after GKSRS

Male

54 (44.6%)

Female

67 (55.4%)

Date of progression was documented for 57 patients
and calculated as described in Methods for the remaining
62 patients. Median PFS was 4.7 (range 3.9-5.4) months
for the combined cohort, 6.8 (range 4.6-8.9) months
for prior grade 2 patients, 4.2 (range 1.9-6.5) months
for grade 3 patients, and 4.3 (range 3.7-4.9) months for
grade 4 patients. PFS was not significantly different by
tumor grade (P=0.20) (Figure 1C). Additional analysis
using target volume as a continuous variable and adjusting for age, sex, initial KPS, multiple lesions, and initial
tumor grade failed to demonstrate a significant difference
in PFS (P=0.14). Multiple lesions were found to be the
sole significant co-variable in the model (P=0.04). We
were able to review imaging data on 81 of the patients
who had progression. Of these, 44 (54.3%) were classified as having marginal progression and 37 (45.7%) were
classified as having distant progression.

Initial WHO tumor grade
(n=119 patients)†
2

19 (16.0%)

3

27 (22.7%)

4

73 (61.3%)

Location (n=132
tumors)‡
Frontal

41 (31.1%)

Temporal

24 (18.2%)

Parietal

17 (12.9%)

Cerebellum

8 (6.1%)

Occipital

6 (4.5%)

Corpus callosum

6 (4.5%)

Insula

5 (3.8%)

Pons

4 (3.0%)

Thalamus

3 (2.3%)

Medulla

1 (0.8%)

Atrium

1 (0.8%)

Not available/unknown

the grade 4 cohort. The overall log-rank test resulted
in P=0.07, and pairwise comparisons demonstrated a
significantly longer survival for the grade 2 cohort in
comparison to the grade 4 cohort (P=0.04) (Figure 1B).

Survival and Lesion Size

16 (12.1%)

*Values are number (percentage) unless otherwise indicated.
†
Data on WHO tumor grade were missing for 2 patients.
‡
Percentages total >100% due to rounding.

compared to 21.4 (range 17.1–25.8) months for
patients with large lesions (>6.7 cm3) (P=0.04). The
overall log-rank test and all pairwise comparisons
were statistically significant at P<0.001, suggesting
a significant decrease in survival with each increase
in tumor grade. Kaplan-Meier curves reported by
tumor grade are shown in Figure 1A.

Survival analyses were also conducted to compare
the association between lesion size and survival. Data
on lesion size were missing for 10 patients, resulting
in a sample size of 111, as reflected in Table 2. Patients
with small lesions had significantly longer OS, with a
median OS of 32.3 (range 25.2-39.5) months compared
to 21.4 (range 17.1-25.8) months for patients with
large lesions (P=0.04). Patients with small lesions also
had a longer OS after GKSRS, with a median of 13.0
(range 8.0-18.0) months compared to 7.4 (range 5.19.6) months for patients with large lesions (P=0.046).
Additionally, patients with small lesions had a longer
PFS after GKSRS, with a median of 6.8 (range 4.8-8.8)
months for those with small lesions versus 4.2 (range
3.5-5.0) months for those with large lesions (P=0.02).
Kaplan-Meier curves comparing survival by size and
grade are shown in Figure 2.

Overall Survival after GKSRS

Progression-Free Survival and Tumor Grade and
Lesion Size

The median OS calculated from the date of GKSRS
for all tumor grades combined was 8.6 (range 6.9-10.4)
months. OS was 12.7 (range 7.8-17.5) months for the
prior grade 2 cohort, 9.7 (range 5.9-13.4) months for
the grade 3 cohort, and 8.2 (range 6.3-10.1) months for

Given the general association between increased
lesion size and decreased PFS after GKSRS and the
lack of association between PFS and tumor grade, we
explored tumor grade and lesion size within a single
PFS analysis (Table 2 and Figure 2). The overall log-
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Table 2. Summary of progression-free survival from time of GKSRS by tumor grade and size

Grade 2
Small

Grade 2
Large

Grade 3
Small

Grade 3
Large

Grade 4
Small

Grade 4
Large

N

9

9

11

15

33

34

No. of events

8

9

11

13

30

34

No. censored

1

0

0

2

3

0

Mean survival (SE)
[95% CI], months

14.9 (7.0)
[1.3-28.6]

9.3 (4.1)
[1.2-17.4]

13.2 (3.7)
[6.1-20.4]

4.1 (1.0)
[2.1-6.1]

7.6 (1.6)
[4.6-10.7]

5.8 (0.9)
[4.0-7.6]

Median survival (SE)
[95% CI], months

8.1 (0.2)
[7.7-8.5]

4.7 (0.5)
[3.6-5.7]

9.7 (1.4)
[7.0-12.4]

3.6 (0.9)
[1.9-5.3]

4.7 (1.0)
[2.7-6.7]

4.0 (0.6)
[2.9-5.1]

3 mo

5

3

6

4.5

15

19

6 mo

3.5

1

6

1

7

9

9 mo

2

1

5

6

5

12 mo

1

1

4

2

24 mo

2

1

36 mo

1

Variable

No. patients exposed
to risk

rank test was significant, suggesting significant differences in PFS after GKSRS by categories combining
tumor grade and lesion size (P=0.03). Within each
tumor grade, both mean and median PFS decreased
when comparing patients with small tumors to those
with large tumors. Pairwise comparisons reflected
significantly shorter survival for patients with grade 3
large tumors versus grade 3 small (P=0.005) and grade
2 small (P=0.02). Patients with grade 4 large tumors
also had significantly shorter PFS than those with grade
3 small tumors (P=0.02). In Figure 2, for significant values described above, refer to the black dotted survival
curve for grade 3 large tumors and black solid curve for
grade 4 large tumors.
Karnofsky Performance Status
Mean KPS values are shown in Table 3 for patients
before the first GKSRS treatment (initial KPS), the
first follow-up visit (mean 1.9±1.0 months), and third
follow-up visit (mean 5.3±2.0 months). The repeated
measures analysis demonstrated a significant effect
of time (P<0.001) with all pairwise comparisons significant at P<0.001 indicating a significant mean drop
from initial KPS to KPS at the date of GKSRS treatment and a significant drop from GKSRS treatment to
first follow-up. Initial KPS was reported for 86 of 121
patients (71%).

Post-GKSRS Adverse Effects
A total of 29 (24%) of the 121 patients had PRTE
at any point following GKSRS salvage treatment as
reported by 2 neuroradiologists. Only 2 (1.7%) patients
had cerebral edema, and 90 (74.4%) patients had no
adverse treatment effect.

DISCUSSION
The prognosis for patients with recurrent disease is
even more dismal than that for patients with newly diagnosed disease, prompting the question of whether any
salvage treatment is justified. Hau et al.(5) addressed
this question in 2003 and reported a superior median
PFS rate at 12 months and OS rate at 24 months in
the reintervention group (71% and 32%, respectively)
compared with a control group who were not re-treated
(15% and 5%, respectively). They also reported a stable or even improved KPS after reintervention in the
patients selected for treatment. Careful patient selection
is important for patients to be considered for reintervention because reports vary widely regarding the benefits
of salvage therapy.
Ideally, salvage treatments for GBM would have
a low treatment burden to the patient with a minimal
recovery time from the treatment because, realistically,
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Figure 2. Progression-free survival by tumor grade and
size after GKSRS. Used with permission of Barrow
Neurological Institute.

Table 3. Summary of mean Karnofsky Performance
Status scores over time after GKSRS

Time Point

N

Mean value
(SE)§

95% CI

Prior to GKSRS

86

87.21 (1.17)

84.92-89.50

First follow-up
visit*

55

79.27 (1.46)

76.41-82.14

Third follow-up
visit†

58

67.59 (1.42)

64.80-70.38

*Mean 1.9±1.0 months after first GKSRS salvage treatment.
†
Mean 5.3±2.0 months after first GKSRS salvage treatment.
§
All pairwise comparisons significant at P<0.001.

Figure 1. Kaplan-Meier curves showing survival by
tumor grade. (A) Overall survival from initial resection.
(B) Overall survival from time of GKSRS salvage
therapy. (C) Progression-free survival from time of
GKSRS salvage therapy. Used with permission of
Barrow Neurological Institute.
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these patients’ life-spans are limited and should not be
spent in the hospital. Salvage treatment options include
(1) possible enrollment in clinical trials; (2) re-resection
with or without a carmustine implant; (3) re-irradiation,
either after re-resection or as stand-alone salvage treatment with IMRT; (4) brachytherapy seed placement after
resection; (5) additional chemotherapy; (6) initiation of
TTF; (7) laser interstitial thermal therapy (LITT); and (8)
SRS. Each modality exhibits a unique profile of advantages and disadvantages. However, the most efficacious
treatment course has yet to be elucidated.
The primary objective of this study was to corroborate
the existing literature regarding the outcomes of patients
treated with GKSRS as salvage therapy for recurrent

GKSRS for recurrent HGG

HGG. Several small prospective and retrospective series
suggest that SRS may provide a survival benefit in recurrent HGG, with postirradiation OS ranging from 7 to
16 months.(2, 6-16) Moreover, 10 additional reports
between 2005 and 2013 for GKSRS for recurrent GBM
demonstrated median OS ranging from 9 to 17.9 months
after salvage SRS, and the median PFS ranged from 4.6
to 14.9 months.(4, 17-25) Our study, which to our knowledge is the largest series to date, obtained similar results
with median OS after GKSRS of 8.6 (range 6.9-10.4)
months and a median PFS of 4.7 (range 3.9-5.4) months.
These results suggest a meaningful survival benefit to
patients that is comparable to other salvage treatments.
For example, a recent series of 37 patients found that
the median PFS and OS after re-irradiation using IMRT
without and with BVZ was 5.1 (range 1.6-17.4) months
and 9.0 (range 6.4-17.8) months, respectively.(26) Chan
et al.(27) treated 24 patients with recurrent GBM with
re-resection followed by GliaSite brachytherapy, resulting in a median survival time of 9.1 months. Another
study of permanent brachytherapy showed similar outcomes with a median OS posttreatment of 10.5 to 12.0
months.(6) However, significant symptomatic radiation
toxicity was reported, leading clinicians to disfavor this
technique.(28)
A challenging factor in treating recurrent GBM is the
inherent difficulty of differentiating true tumor progression from pseudoprogression or PRTE using modern
imaging techniques.(29-31) In many cases, the patient
has a mixture of both tumor recurrence and PRTE
simultaneously. One study found that tumor recurrence
or a mixture of tumor recurrence and PRTE was twice
as likely as PRTE alone after radiation therapy for primary brain gliomas.(32, 33) This confounding variable
can result in inappropriate treatment because prescribing any form of additional radiation for patients with
PRTE results worsens PRTE.
An important distinction should be drawn between
symptomatic and nonsymptomatic PRTE. Asymptomatic small areas of necrotic tissue within the margins
of treatment are in many regards a desired treatment
response after salvage SRS. It is only considered a
negative response to treatment when the PRTE extends
beyond treatment margins with evidence of associated
symptoms due to edema and mass effect on adjacent
viable tissue. The incidence of patients experiencing
symptomatic PRTE following SRS has been reported in
multiple series, ranging from 6 to 24%, which is similar to that found in our series (24%).(22, 34-37) PostSRS PRTE appears to be relatively less problematic than
PRTE reported after brachytherapy, likely due to smaller
overall volumes of treatment.
Inherent limitations of a nonrandomized, retrospective, single-institution study with a heterogeneous sample of patients include selection bias. In general, our

patients were selected for salvage GKSRS when they
exhibited relatively small areas of nodular tumor recurrence, which did not induce significant mass effect that
would have required surgical resection, or when the
recurrence was in a deep and relatively difficult location
for surgical access. Patients with larger tumor burdens
requiring surgical decompression or with diffuse disease
and declining clinical status were not chosen for GKSRS
salvage therapy and were typically referred for hospice
care. Multifocal nodular disease was not a contraindication for GKSRS, and its presence may have skewed the
decision toward salvage GKSRS because multifocal surgical approaches were felt to be contraindicated or excessively burdensome to these patients.
Our retrospective long-term outcome data from a
large cohort of select patients, with focal nodular areas
of presumed recurrent disease, suggest that salvage
GKSRS offers an effective means of adding modest, but
meaningful, increased survival in these patients with
minimal treatment burden or recovery time and minimal long-term risk of adverse events. We do not suggest
that GKSRS is the best or even the first option for these
patients. We encourage enrollment of these patients into
well-designed clinical trials, ideally with tissue confirmation and molecular profiling-guided targeted therapies in the hope of gaining improved outcomes for these
and future patients with this disease. However, salvage
therapy with low-dose, low-volume GKSRS is an
acceptable treatment option for patients with recurrent
GBM who are unwilling to undergo invasive surgery or
enroll in clinical trials of experimental therapies.
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